71
Six months ago, it was not clear if Apeiron biologics would market its neuroblastoma treatment dinutuximab beta on its own or through a partnership, according to CEO Hans Loibner. Now, the small Austrian company has decided how it will compete against the large US company United Therapeutics, which got FDA approval for a similar antibody last year. British EUSA Pharma has acquired the exclusive global commercialisation rights for the cancer immunotherapy that targets glycolipid GD2, expressed on neuroblastoma cells and on normal cells. Dinutuximab beta, which Apeiron has filed for EU approval, is currently used as part of the regimen for the…